BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35379108)

  • 1. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
    Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
    Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
    Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
    J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
    Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
    JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
    Goljan E; Abouelhoda M; ElKalioby MM; Jabaan A; Alghithi N; Meyer BF; Monies D
    PLoS One; 2022; 17(1):e0263137. PubMed ID: 35089958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing.
    Ly RC; Shugg T; Ratcliff R; Osei W; Lynnes TC; Pratt VM; Schneider BP; Radovich M; Bray SM; Salisbury BA; Parikh B; Sahinalp SC; Numanagić I; Skaar TC
    J Mol Diagn; 2022 Jun; 24(6):576-585. PubMed ID: 35452844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational pharmacogenotype extraction from clinical next-generation sequencing.
    Shugg T; Ly RC; Osei W; Rowe EJ; Granfield CA; Lynnes TC; Medeiros EB; Hodge JC; Breman AM; Schneider BP; Sahinalp SC; Numanagić I; Salisbury BA; Bray SM; Ratcliff R; Skaar TC
    Front Oncol; 2023; 13():1199741. PubMed ID: 37469403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
    Lanillos J; Carcajona M; Maietta P; Alvarez S; Rodriguez-Antona C
    NPJ Genom Med; 2022 Feb; 7(1):12. PubMed ID: 35181665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays.
    Geck RC; Boyle G; Amorosi CJ; Fowler DM; Dunham MJ
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():531-550. PubMed ID: 34516287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for rare variants in drug metabolism genes and the clinical implications.
    Drögemöller BI; Wright GE; Warnich L
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):873-84. PubMed ID: 24673405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic profile of a central European urban random population-Czech population.
    Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
    PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population.
    Goljan E; Abouelhoda M; Tahir A; ElKalioby M; Meyer B; Monies D
    Hum Genomics; 2024 Mar; 18(1):30. PubMed ID: 38523294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation.
    Mauleekoonphairoj J; Chamnanphon M; Khongphatthanayothin A; Sutjaporn B; Wandee P; Poovorawan Y; Nademanee K; Pongpanich M; Chariyavilaskul P
    Sci Rep; 2020 Nov; 10(1):18969. PubMed ID: 33144648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico.
    Gonzalez-Covarrubias V; Morales-Franco M; Cruz-Correa OF; Martínez-Hernández A; García-Ortíz H; Barajas-Olmos F; Genis-Mendoza AD; Martínez-Magaña JJ; Nicolini H; Orozco L; Soberón X
    Front Pharmacol; 2019; 10():1169. PubMed ID: 31649539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
    Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
    Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
    Ingelman-Sundberg M; Pirmohamed M
    J Intern Med; 2024 May; 295(5):583-598. PubMed ID: 38343077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
    Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.